Modulating oncolytic vesicular stomatitis virus (VSV) with statins for cancer treatment
US9289456B2 · kind B2 · utility
0Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 22, 2011 |
| Grant date | Mar 22, 2016 |
| Priority date | — |
| Expiry date | May 7, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In the instant invention, simvastatin (Sim) is used to modulate Vesicular Stomatitis Virus (VSV) infection at the level of viral replication for treatment of cancer. Both lipid-lowering and pleiotropic cellular effects of simvastatin are exploited in this modulation. Simvastatin upregulates the expression of Rae1 and Nup98, therefore altering normal cellular mRNA distribution and reverting VSV's mRNA export block. Furthermore, simvastatin causes redistribution of Flotillin-1, which affects VSV replication/budding. Simvastatin is further used as a neoadjuvant for the selective modulatory control of live VSV oncolytic therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.